Effect of Extended Cannabis Abstinence on PTSD Symptoms
Centre for Addiction and Mental Health
24 participants
Feb 2, 2022
INTERVENTIONAL
Conditions
Summary
This will be a 12-week randomized trial. Outpatients and patients from the Mood and Anxiety program at the Centre for Addiction and Mental Health (CAMH) with a current diagnosis of post-traumatic stressed disorder (PTSD) and cannabis-use disorder (CUD) will be randomized to receive individual motivational interviewing therapy and contingency management (n = 12) or individual motivational interviewing therapy alone (control group, n = 12) after enrolment.
Eligibility
Inclusion Criteria6
- Subjects aged between 18 and 55 years (from both sexes \[or genders\]);
- Diagnosed with CUD (moderate or severe) according to the Structured Clinical Interview for DSM-IV (SCID) (mode of cannabis consumption can be inhalation or ingestion);
- Diagnosis of current (past 30 days) PTSD, using the CAPS-5 on screening;
- On antidepressant medication(s) for at least 1 month (to ensure safety and homogeneity as PTSD treatment of our population);
- Be able to provide written informed consent; and
- Be able to communicate in English.
Exclusion Criteria4
- diagnosed with a severe or unstable medical illness that precludes safe participation in the study as per the study physician;
- diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder or current acute psychosis or mania based on DSM-5 criteria;
- current suicidality risk as indicated by the Columbia Suicide Severity Rating Scale (C-SSRS) with concurrence after the study physician's evaluation if the response to C-SSRS questions 1 or 2 is "yes" 34; and
- have pain interfering with normal function as reported by the 12-Item Short Form Survey (SF-12) (moderate or higher interference).
Interventions
In addition to structured assessments at baseline, four, eight and twelve months, subjects randomized to the contingency-management group will receive a contingent bonus if the participants show successful abstinence at the end of weeks 4, 8 and 12.
Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05162651